Posts

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study

/in

Link to Full Article Data from Phase 2a Study Demonstrated Patients Treated with Auxora Experienced Reduced Severity of Acute Pancreatitis, Less Persistent Systemic Inflammatory Response Syndrome (SIRS) and More Rapid Restoration of Gut Function with Favorable Safety Profile Patient dosing has begun in Phase 2b study in acute pancreatitis; data expected H2 2022 LA JOLLA, […]

Read more

Acrux Receipt of R&D Tax Incentive Rebate – Overseas Finding Application for Acrux Pharma Pty Ltd

/in

Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]

Read more

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

/in

Link to Full Article Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided […]

Read more

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

/in

Link to Full Article MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the fourth quarter and full year 2020 and provided a corporate and clinical update. Fourth Quarter […]

Read more

CalciMedica Announces $21 Million Series D Financing

/in

Link to Full Article Round led Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Zafi Avnur, Ph.D., chief scientific officer and partner at Quark Venture, joins Board of Director LA JOLLA, […]

Read more

BIOSCIENCE MANAGERS: This biotech focused fund explains why it invested $15m in these 2 ASX stocks

/in ,

Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]

Read more

Acrux (ASX:ACR) receives $15M in applications for $2M SPP

/in

Link to Full Article Acrux (ACR) has wrapped up a share purchase plan that was more than seven times oversubscribed after receiving approximately $15.1 million in applications The placement has since been scaled back to roughly $9.9 million, but still marks a significant increase on the $2 million it was initially seeking ACR says funds […]

Read more

CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress

/in

D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe […]

Read more

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs

/in

Link to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]

Read more

Acrux receives FDA approval for its generic testosterone topical solution

/in

Link to Full Article Melbourne, Australia; 12 January 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic product based on Perrigo’s Testosterone Topical Solution, 30mg/1.5mL. In August 2018, Acrux submitted an Abbreviated New Drug Application (‘ANDA’) to seek approval from […]

Read more